{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:21:29Z","timestamp":1763767289828,"version":"3.40.5"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>Even if now we have available the weapon of vaccination against SARS-CoV-2, the patients with cancer remains a very frail population in which frequently the immunologic response to vaccination may be impaired. In this setting, the SARS-CoV-2 infection screening retains a great value. However, there are still limited data on the feasibility and efficacy of combined screening procedures to assess the prevalence of SARS-CoV-2 infection (including asymptomatic cases) in cancer outpatients undergoing antineoplastic therapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Patients and results<\/jats:title>\n<jats:p>From May 1, 2020, to June 15, 2020, during the first wave of SARS-CoV-2 pandemic, 860 consecutive patients, undergoing active anticancer therapy, were evaluated and tested for SARS-CoV-2 with a combined screening procedure, including a self-report questionnaire, a molecular nasopharyngeal swab (NPS) and a rapid serological immunoassay (for anti-SARS-CoV-2 IgG\/IgM antibodies). The primary endpoint of the study was to estimate the prevalence of SARS-CoV-2 infection (including asymptomatic cases) in consecutive and unselected cancer outpatients by a combined screening modality. A total of 2955 SARS-CoV-2 NPS and 860 serological tests, in 475 patients with hematologic cancers and in 386 with solid tumors, were performed. A total of 112 (13%) patients self-reported symptoms potentially COVID-19 related. In 1\/860 cases (&lt; 1%) SARS-CoV-2 NPS was positive and in 14 cases (1.62%) the specific serological test was positive (overall prevalence of SARS-CoV-2 infection 1.62%). Of the 112 cases who declared symptoms potentially COVID-19-related, only 2.7% (3\/112) were found SARS-CoV-2 positive.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This is the largest study reporting the feasibility of a combined screening procedure (including triage, NPS and serologic test) to evaluate the prevalence of SARS-CoV-2 infection in cancer patients receiving active therapy, during the first epidemic wave and under the restrictive lockdown measures, in one of the active areas of the SARS-CoV-2 circulation. Lacking specific recommendations for the detection of asymptomatic SARS-CoV-2 cases, a combined diagnostic screening might be more effective to detect the exact prevalence of SARS-CoV-2 in neoplastic patient population. The prevalence can obviously change according to the territorial context, the entity of the restrictive measures adopted and the phase of the epidemic curve. However, its exact and real-time knowledge could be important to balance risks\/benefits of oncologic treatments, avoiding (if the prevalence is low) the reduction of dose intensity or the selection of less intensive (but also less effective) anti-cancer therapies.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0262784","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T18:39:33Z","timestamp":1643827173000},"page":"e0262784","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Detection of SARS-CoV-2 infection prevalence in 860 cancer patients with a combined screening procedure including triage, molecular nasopharyngeal swabs and rapid serological test. A report from the first epidemic wave"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4436-1310","authenticated-orcid":true,"given":"Anna","family":"Candoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Petruzzellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Sperotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Andreotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9345-126X","authenticated-orcid":true,"given":"Marco","family":"Giavarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Corvaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Minisini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Comuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1254-4705","authenticated-orcid":true,"given":"Gianpiero","family":"Fasola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"pone.0262784.ref001","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/14737140.2020.1766355","article-title":"How toface cancer treatment in the COVID-19 era.","volume":"6","author":"A Brandes","year":"2020","journal-title":"Expert Review of Anticancer Therapy."},{"key":"pone.0262784.ref002","first-page":"M20","article-title":"Coronavirus disease 2019 (COVID-19): Protecting hospitals from the invisible.","volume":"11","author":"M. Klompas","year":"2020","journal-title":"Ann Intern Med"},{"issue":"10","key":"pone.0262784.ref003","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1111\/dom.14124","article-title":"Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis","volume":"22","author":"AK Singh","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"pone.0262784.ref004","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M20-3012","article-title":"Prevalence of Asymptomatic SARS-CoV-2 Infection. A Narrative Review","volume":"173","author":"DP Oran","year":"2020","journal-title":"Ann Intern Med"},{"issue":"22","key":"pone.0262784.ref005","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1056\/NEJMe2009758","article-title":"Asymptomatic transmission, the Achilles\u2019 heel of current strategies to control COVID-19","volume":"382","author":"M Gandhi","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0262784.ref006","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1056\/NEJMp2002125","article-title":"Defining the epidemiology of Covid-19 \u2013studies needed","volume":"382","author":"M Lipsitch","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0262784.ref007","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jmii.2020.05.001","article-title":"A systematic review of asymptomatic infections with COVID-19","volume":"54","author":"Z Gao","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"pone.0262784.ref008","unstructured":"European Centre for Disease Prevention and Control (ECDC). Risk Assessment: Risk related to spread of new SARS-CoV-2 variants of concern in the EU\/EEA [updated 29 December 2020; cited 14 January 2021]. Available from: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/covid-19-risk-assessment-spread-new-sarscov-2-variants-eueea."},{"issue":"7","key":"pone.0262784.ref009","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S1470-2045(20)30309-0","article-title":"Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.","volume":"21","author":"J Tian","year":"2020","journal-title":"Lancet Oncol."},{"issue":"18","key":"pone.0262784.ref010","first-page":"1775","article-title":"Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy.","volume":"323","author":"G Onder","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"pone.0262784.ref011","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.","volume":"21","author":"W Liang","year":"2020","journal-title":"Lancet Oncol."},{"issue":"10241","key":"pone.0262784.ref012","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study","volume":"395","author":"LYW Lee","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"pone.0262784.ref013","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort stud","volume":"7","author":"F Passamonti","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"pone.0262784.ref014","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.annonc.2020.03.286","article-title":"Managing COVID-19 in the oncology clinic and avoiding the distraction effect","volume":"31","author":"F Cortiula","year":"2020","journal-title":"Ann. Oncol"},{"issue":"8","key":"pone.0262784.ref015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12032-020-01400-x","article-title":"What to do in an oncology department to face the new COVID-19 era challenges?","volume":"37","author":"SK Garattini","year":"2020","journal-title":"Med Oncol."},{"issue":"4","key":"pone.0262784.ref016","doi-asserted-by":"crossref","first-page":"e694","DOI":"10.1002\/onco.13706","article-title":"Feasibility and Predictive Performance of a Triage System for Patients with Cancer During the COVID-19 Pandemic.","volume":"26","author":"G Fasola","year":"2021","journal-title":"Oncologist"},{"key":"pone.0262784.ref017","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ejca.2021.02.027","article-title":"Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study","volume":"148","author":"S Ladoire","year":"2021","journal-title":"Eur J Cancer"},{"key":"pone.0262784.ref018","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejca.2020.08.011","article-title":"Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies","volume":"139","author":"KS Saini","year":"2020","journal-title":"Eur J Cancer"},{"key":"pone.0262784.ref019","first-page":"1","article-title":"The impact of the COVID-19 pandemic on cancer care","author":"M Richards","year":"2020","journal-title":"Nat Cancer"},{"issue":"10241","key":"pone.0262784.ref020","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.","volume":"395","author":"NM Kuderer","year":"2020","journal-title":"Lancet"},{"key":"pone.0262784.ref021","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41591-020-0874-8","article-title":"Caring for patients with cancer in the COVID-19 era","volume":"26","author":"J Van de Haar","year":"2020","journal-title":"Nat Med"},{"issue":"19","key":"pone.0262784.ref022","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1200\/JCO.20.00960","article-title":"Ethics and Resource Scarcity: ASCO Recommendations for the Oncology Community During the COVID-19 Pandemic.","volume":"38","author":"JM Marron","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"pone.0262784.ref023","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.annonc.2020.07.010","article-title":"Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus.","volume":"31","author":"G Curigliano","year":"2020","journal-title":"Ann Oncol."},{"issue":"9","key":"pone.0262784.ref024","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12032-020-01406-5","article-title":"COVID-19 and cancer care: what do international guidelines say?","volume":"37","author":"A Tartarone","year":"2020","journal-title":"Med Oncol."},{"key":"pone.0262784.ref025","first-page":"1","article-title":"Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal.","author":"M Ueda","year":"2020","journal-title":"J Natl Compr Canc Netw."},{"issue":"4","key":"pone.0262784.ref026","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/onco.13654","article-title":"Prevalence and Clinical Impact of Sars-CoV-2 Silent Carriers Among Actively Treated Cancer Patients During The COVID-19 Pandemic.","volume":"26","author":"A Zambelli","year":"2021","journal-title":"Oncologist"},{"issue":"7","key":"pone.0262784.ref027","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/cncr.33366","article-title":"Triage process for the assessment of coronavirus disease 2019-positive patients with cancer: The ONCOVID prospective study.","volume":"127","author":"A Indini","year":"2021","journal-title":"Cancer"},{"issue":"7","key":"pone.0262784.ref028","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.annonc.2020.04.002","article-title":"Testing for COVID-19 in lung cancer patients","volume":"31","author":"A Passaro","year":"2020","journal-title":"Ann Oncol"},{"issue":"18","key":"pone.0262784.ref029","first-page":"1843","article-title":"Detection of SARS-CoV-2 in Different Types of Clinical Specimens","volume":"323","author":"W Wang","year":"2020","journal-title":"JAMA"},{"key":"pone.0262784.ref030","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1056\/NEJMp2015897","article-title":"False Negative Test for SARS-CoV-2 infection\u2014Challenges and Implications","volume":"383","author":"S Woloshin","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0262784.ref031","doi-asserted-by":"crossref","first-page":"m1808","DOI":"10.1136\/bmj.m1808","article-title":"Interpreting a covid-19 test result","volume":"369","author":"J Watson","year":"2020","journal-title":"BMJ"},{"key":"pone.0262784.ref032","first-page":"M20","article-title":"Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure","author":"LM Kucirka","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"pone.0262784.ref033","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/22221751.2020.1745095","article-title":"Laboratory diagnosis of emerging human coronavirus infections\u2013the state of the art.","volume":"9","author":"MJ Loeffelholz","year":"2020","journal-title":"Emerging Microbes & Infections."},{"issue":"12","key":"pone.0262784.ref034","doi-asserted-by":"crossref","first-page":"785","DOI":"10.18821\/0869-2084-2020-65-12-785-792","article-title":"Detection of SARS-CoV-2 RNA in nasopharyngeal swabs from COVID-19 patients and asymptomatic cases of infection by real-time and digital PCR.","volume":"65","author":"VA Ternovoi","year":"2020","journal-title":"Klin Lab Diagn."},{"key":"pone.0262784.ref035","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/jmv.25990","article-title":"Asymptomatic cases with SARS-CoV-2 infection","volume":"92","author":"Y Wang","year":"2020","journal-title":"J Med Virol"},{"issue":"6","key":"pone.0262784.ref036","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1473-3099(20)30232-2","article-title":"Viral dynamics in mild and severe cases of COVID-19","volume":"20","author":"Y Liu","year":"2020","journal-title":"Lancet Infectious Disease"},{"issue":"15","key":"pone.0262784.ref037","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/cid\/ciaa310","article-title":"Profiling early humoral response to diagnose novel coronavirus disease (COVID-19).","volume":"71","author":"L Guo","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pone.0262784.ref038","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.clon.2020.10.008","article-title":"How Useful is COVID-19 Antibody Testing\u2014A Current Assessment for Oncologists.","volume":"33","author":"PAC Maple","year":"2021","journal-title":"Clinical Oncology"},{"issue":"8","key":"pone.0262784.ref039","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1093\/cid\/ciaa461","article-title":"Antibody detection and dynamic characteristics in patients with Coronavirus Disease 2019.","volume":"71","author":"F Xiang","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0262784.ref040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.annonc.2020.10.473","article-title":"Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2.","volume":"32","author":"A Marra","year":"2021","journal-title":"Ann Oncol."},{"key":"pone.0262784.ref041","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARSCoV-2 in patients with COVID-19","volume":"26","author":"Q-X Long","year":"2020","journal-title":"Nat Med"},{"key":"pone.0262784.ref042","doi-asserted-by":"crossref","first-page":"102102","DOI":"10.1016\/j.ctrv.2020.102102","article-title":"Seroprevalence of SARS-COV-2-specific antibodies in cancer outpatients in Madrid (Spain): a single center, prospective, cohort study and a review of available data.","volume":"90","author":"L Cabezon-Gutierrez","year":"2020","journal-title":"Cancer Treatment Reviews."},{"issue":"7","key":"pone.0262784.ref043","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3390\/jcm10071503","article-title":"Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy.","volume":"10","author":"L Cantini","year":"2021","journal-title":"J Clin Med."},{"key":"pone.0262784.ref044","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41571-020-0362-6","article-title":"Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic.","volume":"17","author":"TP Hanna","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0262784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T18:40:03Z","timestamp":1643827203000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0262784"}},"subtitle":[],"editor":[{"given":"Padmapriya P.","family":"Banada","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0262784","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,2,2]]}}}